Think

Search This Blog

F.D.A. Panel Recommends Pulling Preterm Birth Drug From the Market

October 19, 2022

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

The agency has weighed years of study that showed the treatment given accelerated approval 11 years ago was not effective.

BY CHRISTINA JEWETT | NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?

BY EMILY ANTHES | NYTimes Health | Disclosure

A new drug slashes deaths among patients with severe Covid, the drug’s developer claims.

BY RONI CARYN RABIN | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

Close to Half of American Adults Infected With Genital HPV, Study Finds

According to a survey published by the National Center for Health Statistics, more than 42 percent of Americans between the ages of 18 and 59 are infected with genital human papillomavirus (HPV). By NICHOLAS BAKALAR via NYT Health

F.D.A. Panel Recommends Pulling Preterm Birth Drug From the Market

The agency has weighed years of study that showed the treatment given accelerated approval 11 years ago was not effective.

Comments

Post a Comment